DUBLIN, Feb. 16, 2018 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced that its data will be featured during
the 2018 American Academy of Dermatology (AAD) Annual Meeting in
San Diego, February 16-20, 2018.
The meeting will be held at the San
Diego Convention Center and the scheduled times (noted in
local Pacific Time) for the Allergan presentations, titles and
authors are as follows:
Podium Presentations
Once-Daily Oral Sarecycline 1.5 mg/kg/day for Moderate to Severe
Acne Vulgaris: Pooled Data From Two Phase 3 Pivotal Studies
- Authors: Leon H. Kircik,
Neal D. Bhatia, Edward Lain, Angela
Moore, Joel Schlessinger,
Linda Stein-Gold, Stephen K. Tyring, Carsten Schmitz, Terry
I. Boodhoo, David R. Berk,
Alexandre Kaoukhov
- Saturday, 2/17, 9:24 - 9:36 AM,
Room 6D
Serial Photographic Assessment of Effect of Oxymetazoline Cream
1.0% on Persistent Facial Erythema of Rosacea
- Authors: Lawrence F.
Eichenfield, James Q. Del
Rosso, Jerry K.L. Tan,
Julie Harper, Leon H. Kircik, Adelaide
A. Hebert, Hilary E. Baldwin,
Linda Stein-Gold, Guy F. Webster, Alexandre Kaoukhov, Nancy Alvandi
- Saturday, 2/17, 10:00 – 10:12 AM,
Room 6D
Oral Poster Presentations
Topical Oxymetazoline Hydrochloride 1.0% Effectively Reduces
Persistent Facial Erythema of Rosacea on Day 1
- Authors: Emil A. Tanghetti,
Jeffrey S. Dover, David J. Goldberg, Sunil
S. Dhawan, Yiyong Fu,
David Berk, Gurpreet Ahluwalia, Nancy Alvandi
- Saturday, 2/17, 9:35 – 9:40 AM,
e-Poster Presentation Center 2
Poster Presentations
OnabotulinumtoxinA for Treatment of Moderate to Severe
Horizontal Frontalis Lines and Glabellar Lines From the Subject's
Perspective: Patient-Reported Satisfaction and Impact Outcomes From
a Phase 3 Double-Blind Study
- Authors: Dayan S, Ogilvie P, Rivkin; Yoelin S, Ferrusi I
- Available for online viewing during program
Simultaneous Treatment of Moderate to Severe Horizontal
Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines With
OnabotulinumtoxinA From the Subject's Perspective: Patient-Reported
Satisfaction and Impact Outcomes From a Phase 3 Double-Blind
Study
- Authors: Dayan S, Ogilvie P, Rivkin; Yoelin S, Ferrusi I
- Available for online viewing during program
Efficacy, Safety, and Patient-Reported Outcomes in Male Subjects
Treated With OnabotulinumtoxinA for Improvement of Moderate to
Severe Horizontal Forehead Lines
- Authors: Keaney T, Cavallini M, Leys C, Rossi A, Mao C, Garcia
J, Gallagher C, Shumate G
- Available for online viewing during program
In Vitro Inflammatory and Immune Response to Uncrosslinked
Hyaluronic Acid (HA) and HA Fillers
- Authors: Hee C, Nakab L, Messina D
- Available for online viewing during program
Role of Bacteria on the In Vitro Immune Response to Hyaluronic
Acid Fillers
- Authors: Hee C, Messina D
- Available for online viewing during program
Differential Facial Aesthetic Treatment Considerations for Skin
of Color Populations: African American, Asian, and Hispanic
- Authors: Boyd C, Chiu A, Montes JR, Narurkar V, Shumate G,
Gallagher C
- Available for online viewing during program
Maximizing Panfacial Aesthetic Outcomes: Findings and
Recommendations From the HARMONY Study
- Authors: Kaminer M, Cohen J, Narurkar V, Shamban A, Werschler
P, Shumate G, Gallagher C
- Available for online viewing during program
Long-term Topical Oxymetazoline Hydrochloride 1.0% Demonstrates
Sustained and Increasing Effect in Persistent Facial Erythema of
Rosacea
- Authors: Gold M, Lebwohl M, Biesman B, Robinson E, Fu Y, Berk
D, Ahluwalia G, Alvandi N
- Available for online viewing during program
Improvements in Submental Fat Achieved With ATX-101 (Deoxycholic
Acid Injection) Are Maintained Over Time: 3-Year Follow-up Data
From the Phase 3 REFINE Trials
- Authors: Humphrey S, Bhatia A, Green L, Cohen J, Green J, Liu
C, Somogyi C
- Available for online viewing during program
ATX-101 (Deoxycholic Acid Injection) Leads to Clinically
Meaningful Improvement in Submental Fat: Final Data From
CONTOUR
- Authors: Beer K, Callender V, Fagien S, Munavalli G, Fabi S,
Sadick N, Orejudos A, Gallagher C
- Available for online viewing during program
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; uncertainty
associated with financial projections, projected cost reductions,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2016
and Allergan's Quarterly Report on Form 10-Q for the period ended
September 30, 2017. Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Daphne
Karydas
|
|
(862)
261-8006
|
|
|
|
Media:
|
|
Mark
Marmur
|
|
(862)
261-7558
|
|
|
|
Lisa Brown
|
|
(862)
261-7320
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/allergan-presents-data-at-the-2018-american-academy-of-dermatology-aad-annual-meeting-in-san-diego-300600369.html
SOURCE Allergan plc